Drug Store News5d
FDA approves new indication for Novo Nordisk’s Ozempic
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
Novo Nordisk Earnings Boost Stock in Ozempic Maker
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...
Gizmodo26d
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
This week, Novo Nordisk ... dose lost around 20% of their baseline weight over a 72 week period. The findings exceed the typical weight loss results seen with the existing semaglutide-based drugs ...
MarketWatch18d
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish ... achieved weight loss of 22% on a 20 milligram once-per-week dose taken for 36 weeks. Steven Goldstein is based in London and responsible ...
pharmaphorum13d
Ozempic is first GLP-1 drug FDA-approved for kidney disease
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...
PMLiVE14d
Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease
Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food ... after Novo shared positive headline results from a late-stage study evaluating a higher dose of semaglutide in adults with ...